Home / Search Results

Search Results

You searched for:

March is Multiple Myeloma Awareness Month. Learn more about the work ACCC is doing to support oncology professionals in treating patients with this disease.
The first post in ACCC's "Subspeciality Immuno-Oncology Insights" series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.
With the treatment of chronic lymphocytic leukemia (CLL) shifting substantially in the last five years, learn how ACCC is supporting oncology professionals in integrating oral oncolytics in CLL practice.
ACCCBuzz spoke with Dr. Dan Vogl to learn more about the treatment options available to patients with multiple myeloma, including the benefits of adding anti-CD38 monoclonal antibodies in either first- or second-line treatment.
Tennessee Oncology is a physician-led private oncology practice based in Nashville, with 32 clinic locations across the state and one in northern Georgia- offering medical and radiation oncology, imaging, and lab services.
Patients receiving anti-cancer infusions often experience lengthy appointment wait times due to the highly complex nature of their care. To address this lack in communication, Vanderbilt-Ingram Cancer Center developed a digital wallboard to better inform patients of their appointment status.
An expert ACCC Steering Committee shares 32 informed treatment and care delivery recommendations for the ideal care of patients with non-small cell lung cancer.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.
Though the incidence of AIDS-defining cancers has decreased with the use of antiretroviral therapy, numerous studies suggest that non-AIDS-defining cancers (cancers not previously associated with HIV and AIDS) appear to be increasing in incidence.